Adial Pharmaceuticals, Inc. ADIL
We take great care to ensure that the data presented and summarized in this overview for ADIAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADIL
View allLatest Institutional Activity in ADIL
Top Purchases
Top Sells
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Insider Transactions at ADIL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 29
2023
|
Kevin Schuyler Director |
BUY
Open market or private purchase
|
Direct |
700
+50.0%
|
$1,400
$2.74 P/Share
|
|
May 23
2023
|
Joseph Truluck Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
157,500
+37.27%
|
-
|
|
May 23
2023
|
William B. Stilley Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
240,800
+16.03%
|
-
|
|
May 23
2023
|
Cary J Claiborne Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
420,000
+21.65%
|
-
|
|
Dec 30
2022
|
William B. Stilley Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
166,667
-14.03%
|
-
|
|
Sep 20
2022
|
Cary J Claiborne Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+6.38%
|
$0
$0.42 P/Share
|
|
Sep 19
2022
|
Cary J Claiborne Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+2.38%
|
$0
$0.43 P/Share
|
|
Aug 18
2022
|
Cary J Claiborne Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+50.0%
|
-
|
|
Feb 23
2022
|
William B. Stilley Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+17.39%
|
-
|
|
Dec 30
2021
|
James W. Newman Jr. Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+15.73%
|
$30,000
$2.72 P/Share
|
|
Dec 30
2021
|
James W. Newman Jr. Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$20,000
$2.66 P/Share
|
|
Dec 23
2021
|
Kevin Schuyler Director |
SELL
Bona fide gift
|
Direct |
312,990
-100.0%
|
-
|
|
Nov 30
2021
|
William B. Stilley Iii Director |
BUY
Open market or private purchase
|
Direct |
10,600
+1.12%
|
$21,200
$2.75 P/Share
|
|
Nov 29
2021
|
William B. Stilley Iii Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.07%
|
$20,000
$2.59 P/Share
|
|
Nov 26
2021
|
James W. Newman Jr. Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+22.48%
|
$20,000
$2.85 P/Share
|
|
Oct 04
2021
|
Bankole A. Johnson Director |
SELL
Open market or private sale
|
Indirect |
200,000
-57.43%
|
-
|
|
Apr 06
2021
|
Bankole A. Johnson Director |
SELL
Open market or private sale
|
Indirect |
150,000
-21.48%
|
$300,000
$2.5 P/Share
|
|
Jan 26
2021
|
James W. Newman Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,731
+4.61%
|
-
|
|
Jan 26
2021
|
William B. Stilley Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
201,109
+17.99%
|
-
|